A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC
The purpose of this study is to evaluate the efficacy and tolerability of poziotinib in patients with HER2-positive metastatic breast cancer who have received at least 2 prior HER2-directed treatment regimens.
James Lechner, M.D.
Spectrum Pharmaceuticals, Inc
- Providence Regional Cancer System - Lacey